HK1252156A1 - 藥物製劑 - Google Patents

藥物製劑

Info

Publication number
HK1252156A1
HK1252156A1 HK18111548.4A HK18111548A HK1252156A1 HK 1252156 A1 HK1252156 A1 HK 1252156A1 HK 18111548 A HK18111548 A HK 18111548A HK 1252156 A1 HK1252156 A1 HK 1252156A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
HK18111548.4A
Other languages
English (en)
Inventor
J‧科齊亞拉
D‧斯佩格
Original Assignee
吉利德科學公司
愛爾蘭詹森科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 吉利德科學公司, 愛爾蘭詹森科學公司 filed Critical 吉利德科學公司
Publication of HK1252156A1 publication Critical patent/HK1252156A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18111548.4A 2015-06-30 2018-09-07 藥物製劑 HK1252156A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187102P 2015-06-30 2015-06-30
US201662296524P 2016-02-17 2016-02-17

Publications (1)

Publication Number Publication Date
HK1252156A1 true HK1252156A1 (zh) 2019-05-17

Family

ID=56413867

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18111548.4A HK1252156A1 (zh) 2015-06-30 2018-09-07 藥物製劑
HK18113419.6A HK1254343A1 (zh) 2015-06-30 2018-10-18 藥物製劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18113419.6A HK1254343A1 (zh) 2015-06-30 2018-10-18 藥物製劑

Country Status (16)

Country Link
US (1) US20170027967A1 (zh)
EP (1) EP3316869A1 (zh)
JP (2) JP2018519325A (zh)
KR (2) KR20180048584A (zh)
CN (1) CN107921003A (zh)
AU (1) AU2016285916B9 (zh)
BR (1) BR112017028140A2 (zh)
CA (1) CA2921336A1 (zh)
EA (1) EA201792591A1 (zh)
HK (2) HK1252156A1 (zh)
IL (1) IL256491A (zh)
MA (1) MA42303A (zh)
MX (1) MX2017016802A (zh)
NZ (1) NZ738524A (zh)
SG (1) SG10201912530XA (zh)
WO (1) WO2017004012A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2822954E (pt) 2012-12-21 2016-06-16 Gilead Sciences Inc Compostos carbamoilpiridona policíclicos e seu uso farmacêutico
KR20170123308A (ko) 2014-12-26 2017-11-07 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
ES2757560T3 (es) 2015-11-09 2020-04-29 Gilead Sciences Inc Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
CA3077624A1 (en) * 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
TWI820984B (zh) 2017-01-31 2023-11-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2019242604A1 (en) * 2018-03-25 2020-10-22 Pfizer Ireland Pharmaceuticals Rimegepant for CGRP related disorders
KR102281373B1 (ko) 2018-04-26 2021-07-22 주식회사 엘지에너지솔루션 고체 전해질 전지용 양극 및 그를 포함하는 고체 전해질 전지
KR102016952B1 (ko) * 2019-04-19 2019-09-02 유니셀랩 주식회사 신규한 결정형 형태의 항바이러스제 및 이의 제조방법
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103491948B (zh) * 2010-11-19 2016-11-02 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
EP2809323A1 (en) * 2012-02-03 2014-12-10 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
EP3033084A1 (en) * 2013-08-14 2016-06-22 ratiopharm GmbH Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir

Also Published As

Publication number Publication date
AU2016285916A1 (en) 2018-01-18
JP2019116514A (ja) 2019-07-18
NZ738524A (en) 2019-02-22
WO2017004012A1 (en) 2017-01-05
HK1254343A1 (zh) 2019-07-19
AU2016285916B9 (en) 2019-04-04
BR112017028140A2 (pt) 2018-08-28
MX2017016802A (es) 2018-09-06
EA201792591A1 (ru) 2018-06-29
KR20200037880A (ko) 2020-04-09
KR20180048584A (ko) 2018-05-10
CN107921003A (zh) 2018-04-17
IL256491A (en) 2018-02-28
AU2016285916B2 (en) 2019-03-07
CA2921336A1 (en) 2016-12-30
JP2018519325A (ja) 2018-07-19
MA42303A (fr) 2018-05-09
EP3316869A1 (en) 2018-05-09
US20170027967A1 (en) 2017-02-02
SG10201912530XA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
IL246978A0 (en) New paracetamol formulations
PT4070788T (pt) Formulações farmacêuticas
HK1254343A1 (zh) 藥物製劑
ZA201903101B (en) Pharmaceutical formulations
IL262745A (en) Improved preparations containing drugs
GB201604124D0 (en) Pharmaceutical formulation
IL253177A0 (en) Pharmacy preparation
HK1245653A1 (zh) 藥物製劑
ZA201707094B (en) Pharmaceutical formulations
GB201521462D0 (en) Pharmaceutical composition
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
GB201515310D0 (en) Pharmaceutical composition
HK1245073A1 (zh) 藥物組合物
GB201520862D0 (en) Pharmaceutical composition
GB201506755D0 (en) Novel pharmaceutical formulation
GB201511246D0 (en) Pharmaceutical formulation
IL271908A (en) Over-compressed pharmaceutical preparations
GB201417589D0 (en) Pharmaceutical Formulations
GB201610440D0 (en) Pharmaceutical formulations
PL3319596T3 (pl) Farmaceutyczne kompozycje
GB201521456D0 (en) Pharmaceutical composition
GB201506598D0 (en) Pharmaceutical compositions
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations